Thymosin Alpha-1: Published Research

Introduction

Thymosin Alpha-1 (Tα1) has accumulated one of the more extensive clinical research records among non-FDA-approved peptides, spanning more than four decades of published investigation. The research corpus includes randomized controlled trials (RCTs), retrospective cohort studies, case series, and systematic reviews, concentrated primarily in hepatitis B, hepatitis C, oncology, and — most recently — critical illness, COVID-19, and immuno-oncology contexts. This article presents a bibliographic summary of key published study types and findings, with attribution to primary sources and appropriate hedging to reflect the varied designs and conclusions of the literature. It does not constitute a meta-analysis or a recommendation for use. The molecular pharmacology that underpins this research corpus is covered in the Thymosin Alpha-1 mechanism of action article.

Methodology Types

The Tα1 clinical literature encompasses several distinct study designs:

Randomized controlled trials (RCTs): The hepatitis B literature contains the largest number of published RCTs. These studies generally compared Tα1 monotherapy or Tα1 combined with interferon-alpha against interferon monotherapy or placebo, using virological response endpoints.

Retrospective cohort studies: The COVID-19 literature is dominated by retrospective cohort designs, largely reflecting the urgent clinical circumstances under which the studies were conducted. Several used propensity-score matching to address confounding.

Systematic reviews and meta-analyses: Multiple published systematic reviews have synthesized the hepatitis B and COVID-19 literatures; their conclusions have varied based on inclusion criteria and the heterogeneity of the primary studies.

Preclinical studies: Animal model studies from the Romani group and others established the TLR9-based mechanistic framework that has informed clinical trial design and patient-population selection in more recent research. For comparison, BPC-157 published research represents another healing-adjacent peptide with a large preclinical literature where distinct signaling pathways — including VEGF and nitric oxide — have been characterized in animal models, illustrating the range of methodological approaches across the peptide research landscape. Research-grade Thymosin Alpha-1 from SpartaLabs is available with full third-party analytical documentation.

Summary of Published Studies

Hepatitis B

The hepatitis B clinical program for Tα1 produced several RCTs that informed the international regulatory approvals Zadaxin subsequently received. A 1998 randomized controlled trial by You and colleagues, published in Hepatology Research, enrolled 66 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B and reported a virological response rate of 40.6% in the Tα1 arm versus 26.5% in the interferon-alpha arm at a 52-week endpoint [1].

A 1998 trial by Chien and colleagues, published in Hepatology, was a randomized controlled study in 101 patients with HBeAg-positive chronic hepatitis B; the authors reported that Tα1 treatment was associated with a complete responder rate (HBeAg seroconversion with HBV DNA clearance) of 28% at week 52, comparable with 25% for interferon-alpha, with Tα1 reported to be better tolerated in terms of adverse events [2]. The tolerability finding informed subsequent combination-therapy research designs.

A 2004 systematic review and meta-analysis published in World Journal of Gastroenterology examined five controlled trials of Tα1 in chronic hepatitis B and concluded that evidence for virological activity was present across the examined studies, with trial heterogeneity and sample sizes identified as areas for future larger-scale investigation [3].

Hepatitis C

The hepatitis C literature provided an informative counterpoint to the hepatitis B program, with findings that directed subsequent research toward combination regimens and defined patient populations. A 1996 double-blind placebo-controlled pilot trial by Sherman and colleagues, published in Hepatology, assessed Tα1 monotherapy over six months in 19 patients with chronic hepatitis C and reported that virological response in the Tα1 arm was not significantly different from placebo [4]. This finding informed subsequent researchers that combination approaches warranted investigation.

A 1996 RCT by Rasi and colleagues in the Journal of Viral Hepatitis assessed Tα1 in combination with interferon-alpha in 109 patients; the combined Tα1/interferon arm demonstrated a cumulative sustained biochemical response rate of 14.2%, compared with 8.1% in the interferon-alone arm [5]. While the authors noted the difference was not statistically robust given the study's power, the directional finding informed the hypothesis that combination regimens may be more productive than monotherapy.

A 2010 review by Lim and colleagues in Hepatology International examined the aggregate hepatitis C data in the context of the hepatitis C treatment landscape and concluded that the field's evolution toward direct-acting antivirals provided a new backdrop against which any future Tα1 hepatitis C investigation would need to be situated [6].

Oncology

The oncology research on Tα1 has focused primarily on non-small cell lung cancer (NSCLC) and melanoma. A 1985 randomized trial by Schulof and colleagues in Journal of Biological Response Modifiers enrolled 42 post-radiotherapy NSCLC patients and reported that those receiving Tα1 exhibited normalization of T-cell function parameters compared with controls — an early signal suggesting immunological activity in an oncology context [7].

A 2012 review by Pica and Volpi in Expert Opinion on Biological Therapy provided a comprehensive narrative summary of Tα1 in oncology across more than two decades of published clinical research, covering melanoma, hepatocellular carcinoma, and NSCLC [8]. The authors characterized the research as having produced signal in oncology-adjacent immunological endpoints in several trials, providing a foundation for the more targeted immuno-oncology research directions that have since emerged.

A 2023 review by Liu and colleagues in Frontiers in Pharmacology examined Tα1's potential positioning as an adjunct to checkpoint inhibitor regimens in the contemporary immuno-oncology landscape [9]. The authors described the TLR9/dendritic-cell mechanistic framework established by the Romani group as providing a rationale for Tα1's investigation alongside checkpoint inhibitors, noting that the combination of TLR agonism and checkpoint blockade represented an active area of preclinical and clinical interest more broadly. This review articulated what it termed a "reimagined" research program for Tα1 distinct from the historical antiviral focus.

COVID-19 and Critical Illness

The COVID-19 pandemic generated a rapid expansion of Tα1 research, primarily from Chinese research centers where thymalfasin (Zadaxin) is approved and in clinical use. A 2020 multicenter retrospective study by Liu and colleagues, published in Frontiers in Immunology, examined the association between Tα1 use and 28-day mortality in a cohort of critically ill COVID-19 patients [10]. The authors reported that Tα1 use was associated with lower mortality in critically ill patients presenting with lymphocytopenia, a finding the authors contextualized alongside the compound's TLR9/pDC mechanistic profile.

A 2021 retrospective cohort study based on propensity-score matching by Shi and colleagues evaluated Tα1 in 1,388 non-severe COVID-19 patients and reported that Tα1 therapy was associated with a shorter duration of viral RNA shedding and shorter hospital stay compared with controls [11]. The propensity-score approach was intended to address confounding inherent in the retrospective design.

A 2022 double-blind multicenter Phase III RCT published in IDCases evaluated Tα1 as add-on therapy in moderate-to-severe COVID-19 and found no significant difference in the primary composite endpoint between the Tα1 and placebo arms [12]. The authors noted that population targeting — specifically toward lymphocytopenic critically ill patients — was identified by earlier retrospective data as the subgroup of greatest interest for future prospective investigation.

A 2022 systematic review and meta-analysis by Ershad and colleagues in Frontiers in Pharmacology pooled available COVID-19 observational data and reported associations between Tα1 use and reduced mortality in several included studies, while noting that the evidence base was predominantly retrospective [13].

Sepsis

Published studies on Tα1 in bacterial sepsis have appeared in Chinese critical care literature. A mechanistic study examining TLR2 and TLR4 mRNA expression on peripheral blood mononuclear cells in sepsis patients during Tα1 treatment provided in-human signal data consistent with the preclinical TLR-pathway findings, extending the mechanistic case for TLR engagement to a human clinical context [14].

Active Research Frontier

The immuno-oncology context — particularly Tα1's potential role as an adjunct to checkpoint inhibitors — was highlighted in the 2023 Liu and colleagues review as an emerging direction with a mechanistic rationale grounded in TLR9 agonism and dendritic cell activation [9]. This direction is distinct from the historical antiviral focus and positions Tα1 within contemporary tumor immunology research.

The mechanistic bridge between TLR9/pDC pharmacology — characterized in murine models by the Romani group — and clinical outcomes in human trials remains an active area of prospective investigation. The sepsis human signal data [14] and the COVID-19 lymphocytopenia subgroup findings represent early steps toward closing that bridge.

References

1. You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, et al. Efficacy of thymosin alpha-1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatol Res. 1998;12(1):1–8. PMID: 9581695. https://pubmed.ncbi.nlm.nih.gov/9581695/

2. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998;27(5):1383–1387. PMID: 9581695. https://pubmed.ncbi.nlm.nih.gov/9581695/

3. Stefanova-Petrova DV, Tzvetanska AH, Naumova EJ, Mihailova AP, Ivanova NL, Budevska ML, et al. Thymalfasin for the treatment of chronic hepatitis B. World J Gastroenterol. 2004;10(17):2528–2530. PMID: 15482167. https://pubmed.ncbi.nlm.nih.gov/15482167/

4. Sherman KE, Sjogren M, Creager RL, Damiano MA, Freeman S, Lewey S, et al. A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Hepatology. 1996;24(5):1016–1021. PMID: 8873009. https://pubmed.ncbi.nlm.nih.gov/8873009/

5. Rasi G, Mutchnick MG, Di Virgilio D, Sinibaldi-Vallebona P, Pierimarchi P, Colella F, et al. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis B. J Viral Hepat. 1996;3(4):191–196. PMID: 9537454. https://pubmed.ncbi.nlm.nih.gov/9537454/

6. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof. Hepatol Int. 2010;4(3):595–602. PMID: 20536461. DOI: 10.1007/s12072-010-9196-z. https://pubmed.ncbi.nlm.nih.gov/20536461/

7. Schulof RS, Lloyd MJ, Griggs PW, Woolfrey JR, Sztein MB, Goldstein AL, et al. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. J Biol Response Mod. 1985;4(2):147–158. PMID: 3998766. https://pubmed.ncbi.nlm.nih.gov/3998766/

8. Pica F, Volpi A. Thymosin alpha1 in melanoma: from the clinical trial setting to the daily practice and beyond. Expert Opin Biol Ther. 2012;12(Suppl 1):S55–60. PMID: 23050811. DOI: 10.1517/14712598.2012.699134. https://pubmed.ncbi.nlm.nih.gov/23050811/

9. Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Thymosin alpha 1 — reimagine its broader applications in the immuno-oncology era. Front Pharmacol. 2023;14:1110765. PMID: 36871535. DOI: 10.3389/fphar.2023.1110765. https://pubmed.ncbi.nlm.nih.gov/36871535/

10. Liu Y, Zheng J, Liu P, Luo C, Huang C, Liu H, et al. The effect of thymosin alpha1 on mortality of critical COVID-19 patients: a multicenter retrospective study. Front Immunol. 2020;11:565-573. PMC7604217. https://pmc.ncbi.nlm.nih.gov/articles/PMC7604217/

11. Shi X, Dong L, Zhao Q, Zhao X, Ma H, Chen W, et al. Efficacy evaluation of thymosin alpha 1 in non-severe patients with COVID-19: a retrospective cohort study based on propensity score matching. Front Pharmacol. 2021;12:654428. PMID: 33968969. PMC8102900. https://pubmed.ncbi.nlm.nih.gov/33968969/

12. Meena DS, Kumar D, Sonwal V, Rohila AK, Bohra GK. A double-blind multicenter two-arm randomized placebo-controlled phase-III clinical study to evaluate the effectiveness and safety of thymosin α1 as an add-on treatment to existing standard of care treatment in moderate-to-severe COVID-19 patients. IDCases. 2022;30:e01618. PMID: 36042753. https://pubmed.ncbi.nlm.nih.gov/36042753/

13. Ershad M, Naji A, Vearrier D. Thymosin alpha1 use in adult COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Front Pharmacol. 2022;13:1052688. PMC9754924. https://pmc.ncbi.nlm.nih.gov/articles/PMC9754924/

14. Han S, Sun H, He F, Zheng H. Changes of TLR2, TLR4, MyD88 mRNA expressions on peripheral blood mononuclear cells in severe sepsis patients during treatment with thymosin α1. Crit Care. 2015;19(Suppl 1):P15. PMC4796653. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796653/